Celltrion completes Canada permit application for Remsima SC
Celltrion completes Canada permit application for Remsima SC
  • Lee Jun-sung
  • 승인 2020.02.19 10:06
  • 댓글 0
이 기사를 공유합니다

Celltrion has completed a permit application to Health Canada for Remsima SC, the world's first infliximab hypodermic autoimmune disease drug, on Feb. 13 (local time).

In order to gain strong competitiveness in the TNF-α inhibitor (self-immune disease treatment) market, Remsima SC was a self-developed antibody biologic drug that was approved for sale by the European Medicines Agency (EMA) in November last year.
Canada's health agency will conduct a licensing review for about a year in the form of

"Biobetter" in recognition of the vast clinical data that Celltrion submitted to the European Medicines Agency (EMA).

Celltrion Remsima SC

Meanwhile, the Food and Drugs Administration (FDA) in the U.S. judged Remsima SC as a "new drug" and, in close consultation with the FDA, Celltrion was exempted from first and second-phase clinical trials and began to receive a three-phase clinical trial in July last year.

Canada is pushing for a "duty-switching policy" to expand the use of biosimilars at the state level to cut down on health care costs, and to allow the use of original medicines only in exceptional cases.

The first to introduce such a strong biosimilar policy is British Columbia, followed by Ontario and Alberta, which are also considering biosimilar switching policy, which is expected to further spread in Canada this year.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

  • #1206, 36-4 Yeouido-dong, Yeongdeungpo-gu, Seoul, Korea(Postal Code 07331)
  • 서울특별시 영등포구 여의도동 36-4 (국제금융로8길 34) / 오륜빌딩 1206호
  • URL: www.koreaittimes.com / m.koreaittimes.com. Editorial Div. 02-578-0434 / 010-2442-9446. Email: info@koreaittimes.com.
  • Publisher: Monica Younsoo Chung. CEO: Lee Kap-soo. Editor: Jung Yeon-jin. Juvenile Protection Manager: Yeon Choul-woong.
  • IT Times Canada: Willow St. Vancouver BC, Canada / 070-7008-0005.
  • Copyright(C) Korea IT Times, Allrights reserved.
ND소프트